Privo Technologies
Privo Technologies is a biotechnology and biopharmaceutical company dedicated to developing innovative therapeutics and localized drug delivery solutions to eliminate cancers, prevent recurrence, and revolutionize oncology treatment. Their mission is to provide better, more accessible, and targeted treatment options worldwide through their PRV™ platform technology. The company engages in clinical trials, research, and collaborations with institutions like the FDA, NCI, and NIDCR, and has received multiple awards and funding to support their groundbreaking work. Led by founder and CEO Manijeh Goldberg, Ph.D., with a team of experienced professionals, Privo is committed to advancing cancer treatment and improving patient outcomes.
Industries
Nr. of Employees
small (1-50)
Privo Technologies
Products
Topical cisplatin transmucosal patch (topical chemotherapy patch)
A nanoengineered, self-adhesive polymeric patch for topical/transmucosal delivery of cisplatin nanoparticles to mucosal and dermal tumors; developed for neoadjuvant and lesion-directed treatment with clinical data from Phase 1/2 and Phase 3 studies in oral cancers.
Sterilizable sustained-release intratumoral injectable
A reconstitutable injectable formulation containing nanoparticle-encapsulated chemotherapeutic and excipients, designed for single-site intratumoral administration with sustained local activity over weeks.
Intraoperative chemotherapy matrix for tumor-bed application
A sterilized, intraoperative drug-eluting matrix intended for placement into the resected tumor bed during surgery to eliminate residual cells and reduce recurrence risk.
Topical cisplatin transmucosal patch (topical chemotherapy patch)
A nanoengineered, self-adhesive polymeric patch for topical/transmucosal delivery of cisplatin nanoparticles to mucosal and dermal tumors; developed for neoadjuvant and lesion-directed treatment with clinical data from Phase 1/2 and Phase 3 studies in oral cancers.
Sterilizable sustained-release intratumoral injectable
A reconstitutable injectable formulation containing nanoparticle-encapsulated chemotherapeutic and excipients, designed for single-site intratumoral administration with sustained local activity over weeks.
Intraoperative chemotherapy matrix for tumor-bed application
A sterilized, intraoperative drug-eluting matrix intended for placement into the resected tumor bed during surgery to eliminate residual cells and reduce recurrence risk.
Services
Clinical trial design and site coordination
Design and execution of Phase 1/2 and Phase 2/3 clinical studies with multi-site activation and site management at major cancer centers.
Expanded access / compassionate use evaluation
Review and management of individual patient requests for investigational agents outside of trials, including assessment of supply, risk/benefit, and coordination of required regulatory and IRB approvals.
Preclinical development and translational studies
Preclinical efficacy and safety studies in relevant models, including companion animal studies to support translational development.
Business development and partnership support
Advisory and collaboration support for identifying and structuring strategic partnerships and industry collaborations to advance clinical and commercial goals.
Clinical trial design and site coordination
Design and execution of Phase 1/2 and Phase 2/3 clinical studies with multi-site activation and site management at major cancer centers.
Expanded access / compassionate use evaluation
Review and management of individual patient requests for investigational agents outside of trials, including assessment of supply, risk/benefit, and coordination of required regulatory and IRB approvals.
Preclinical development and translational studies
Preclinical efficacy and safety studies in relevant models, including companion animal studies to support translational development.
Business development and partnership support
Advisory and collaboration support for identifying and structuring strategic partnerships and industry collaborations to advance clinical and commercial goals.
Expertise Areas
- Localized drug delivery
- Nanoparticle formulation
- Topical and transmucosal patch delivery
- Controlled-release intratumoral therapies
Key Technologies
- Nanoparticle drug encapsulation
- Topical transmucosal patch systems
- Controlled-release intratumoral injectables
- Intraoperative drug-eluting matrices